- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03724149
Transplanting Hepatitis C Lungs Into Negative Lung Recipients (SHELTER)
Open-Labeled Trial Of Direct-acting Antiviral Treatment Of Hepatitis C-Negative Patients Who Receive Lung Transplants From Hepatitis C-Positive Donors
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Subject Selection Criteria
Inclusion Criteria:
- 18-67 years of age
- Obtained agreement for participation from the lung transplant team
- No evident contraindication to lung transplantation other than the underlying lung disorder
- Able to travel to the University of Pennsylvania for routine post-transplant visits and study visits for a minimum of 12 months after transplantation
- No active illicit substance abuse
- Women must agree to use birth control in accordance with Mycophenolate Risk Evaluation and Mitigation Strategy (REMS) following transplant due to the increased risk of birth defects and/or miscarriage
- Both men and women must agree to use at least one barrier method of birth control or remain abstinent following transplant due to risk of HCV transmission
- Inclusion criteria for treatment (not for entry as study patient) will include any detectable HCV RNA by week 4 post-lung transplantation
- Able to provide informed consent
Exclusion Criteria:
- Hepatocellular carcinoma
- HIV positive
- HCV RNA positive
- Hepatitis B surface antigen and/or DNA positive
- Any chronic liver disease (excluding non-alcoholic fatty liver disease (NAFLD)) that is occurring in the setting of persistently elevated liver enzymes (patients with Alpha-1-antitrypsin lung disease without hepatic involvement are eligible)
- Significant fibrosis (≥F2 on the Fibroscan)-for patients with cystic fibrosis, the cutoff will be 11kPa (cutoff for F2 for patients with chronic cholestatic liver disease), whereas for all other patients the cutoff will be 8kPa (the cutoff for fatty liver disease used in the THINKER study).
- Pregnant or nursing (lactating) women
- Known allergy or intolerance to tacrolimus that would require post-transplant administration of cyclosporine, rather than tacrolimus given the drug-drug interaction between cyclosporine and Zepatier/Epclusa
- Pre-transplant treatment with amiodarone given the drug-drug interaction between amiodarone and Epclusa
- Waitlisted for a multi-organ transplant
- Patients with underlying liver disease with or without liver cirrhosis
- Patients with cystic fibrosis who have underlying liver disease
- Re-transplant candidate
- Use of ECMO or mechanical ventilation as a bridge to lung transplantation
- Inability to provide study consent
- Chronic kidney disease with GFR<50 ml/min/1.73 m^2
Relative contraindications for study subjects that will be reviewed on a case-by-case basis by the Lung Transplant Selection Committee and the Principal Investigators:
- Evidence of end organ damage due to diabetes (e.g. retinopathy, nephropathy, ulcerations) and /or brittle diabetes mellitus (e.g. history of diabetic ketoacidosis) and/or uncontrolled diabetes as evidence by a HgbA1C of 7.5-8.5.
- Hematologic: Significant coagulation abnormalities, and/or bleeding diatheses.
- Active or recent solid or liquid malignancy in the past 5 years (apart from select skin malignancies).
- Patient refusal to receive blood products or transfusions during lung transplant surgery.
- Psychosocial: Profound neurocognitive impairment with absence of social support.
- Active mental illness or psychosocial instability
- Inadequate insurance and/or financial support for post-transplant care.
- Evidence of drug, tobacco or alcohol abuse within the past six months and failure to satisfy recommended therapy/services/parameters as indicated by social work staff and/or consult team.
- History of chronic non-adherence to medical recommendations and/or medications
- PRA >10%.
- Severe malnutrition, BMI <18
- Major chronic disabling comorbidity (e.g. lupus, severe arthritis, neurologic diseases, previous stroke with profound residual).
- Symptomatic or severe vascular disease (History of CABG, Aorta-femoral surgery)
Donor Organ Selection Criteria
Broad goal: To include donors with confirmed HCV expected to have acceptable post-transplant graft outcomes based on large retrospective lung transplant studies.
Inclusion criteria for donors:
- Detectable HCV RNA
- Age ≤55 years
- PaO2/FiO2 ≥300 on FiO2 = 100% and PEEP=5
- Cigarette use history ≤20 pack years
- No evidence of cirrhosis
- No prior treatment of HCV with a DAA-based therapy
- Can be isolated hepatitis B Core IgG positive, but cannot have a detectable HBV Core IgM, HBSAg, and/or HBV DNA (positive HBV NAT test)
Donor Exclusion Criteria:
- Donation after circulatory death determination (DCDD)
- HIV positive
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Direct-acting antiviral treatment for HCV
|
Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected.
In this case treatment with Zepatier will be extended to 16 weeks.
Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks.
Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Adverse Events Attributable to HCV Therapy in Post-lung Transplant Patients Post-lung Transplant Patients
Time Frame: Baseline to 52 weeks
|
Baseline to 52 weeks
|
|
Subject Sustained Virologic Response (SVR-12) at 12-weeks Post-treatment
Time Frame: Baseline to 12 weeks
|
The primary outcome measure is Sustained Virologic Response (SVR) rate at 12 weeks (number of subjects with SVR; negative HCV RNA after completing therapy) / (number of subjects treated post-lung transplantation). SVR will be based on the standard definition of SVR-12, defined as an undetectable HCV RNA in a subject's serum 12 weeks after completing treatment for HCV (12 weeks after the subject takes the last dose of Zepatier, Epclusa, or another appropriate antiviral treatment). |
Baseline to 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Peter Reese, MD, MSCE, Perelman School of Medicine at the University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Diseases
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Lung Diseases
- Hepatitis
- Hepatitis C
- Anti-Infective Agents
- Antiviral Agents
- Sofosbuvir-velpatasvir drug combination
- Elbasvir-grazoprevir drug combination
Other Study ID Numbers
- 829397
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Diseases
-
Aveiro UniversityFundação para a Ciência e a TecnologiaNot yet recruitingInterstitial Lung DiseasesPortugal
-
RWTH Aachen UniversityCompletedObstructive Lung DiseasesGermany
-
Guangzhou Institute of Respiratory DiseaseUnknownInterstitial Lung Disease | Transbronchial Lung Cryobiopsy | Surgical Lung Biopsy
-
China-Japan Friendship HospitalXiangya Hospital of Central South University; Peking Union Medical College... and other collaboratorsUnknown
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedInterstitial Lung DiseasesNetherlands
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; Children... and other collaboratorsRecruitingInterstitial Lung DiseasesUnited States
-
Shanghai East HospitalRegend TherapeuticsCompletedInterstitial Lung DiseasesChina
-
Aveiro UniversityFundação para a Ciência e a Tecnologia; Centro Hospitalar do Baixo VougaRecruitingInterstitial Lung Diseases (ILD)Portugal
-
China-Japan Friendship HospitalNot yet recruitingTransbronchial Lung Cryobiopsy
Clinical Trials on Zepatier
-
Radboud University Medical CenterCompletedHepatitis C | Deglutition DisordersNetherlands
-
Kaohsiung Medical University Chung-Ho Memorial...CompletedHepatitis C, ChronicTaiwan
-
Massachusetts General HospitalWithdrawnHepatitis C | Renal Failure ChronicUnited States
-
Taichung Veterans General HospitalMerck Sharp & Dohme LLCTerminatedLiver Transplant Infection | Kidney Transplant Infection | Chronic Hepatitis cTaiwan
-
University of Illinois at ChicagoMerck Sharp & Dohme LLCActive, not recruitingHepatitis C | Hiv | Substance Use Disorders | Coinfection, HIVUnited States
-
Albert Einstein Healthcare NetworkMerck Sharp & Dohme LLC; Davita Clinical ResearchWithdrawn
-
Virginia Commonwealth UniversityCompletedHepatitis C | Kidney TransplantUnited States
-
University of PennsylvaniaMerck Sharp & Dohme LLCCompleted
-
University of Maryland, BaltimoreCompletedRenal Insufficiency, Chronic | Hepatitis C | Disorder of Transplanted KidneyUnited States
-
National Taiwan University HospitalMerck Sharp & Dohme LLCCompleted